Fabien Depis

Founder & Chief Executive Officer TregShield Bio

Fabien Depis, Ph.D. is Founder and CEO of TregShield Bio, developing next-generation organ-selective antibodies engineered to be systemically inactive and conditionally activated within I&I diseased tissues. With over 17 years advancing Treg-targeted therapies, he is an expert in Treg modulation across cancer and autoimmunity. He served as Program Leader and Co-Inventor of the CCR8-targeted tumor Treg antibody GS-1811 at Jounce Therapeutics, now in Phase 1 immuno-oncology development with Gilead. His experience spans TNFR2 at Merrimack, Foralumab (NovImmune), CEL383 (Celsius), DT101 (Dualyx), and Treg cell therapies as Head of Discovery at GentiBio. He trained at Harvard Medical School (Mathis/Benoist) and chairs the Treg Summit (2023-2025).

Seminars

Tuesday 23rd March 2027
Opening Keynote: The Treg Cell Therapy Lifecycle: From Scientific Innovation to Clinical Impact

Right click on the image to save it to your computer.

Fabien Depis